{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:11:34Z","timestamp":1788621094877,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821283"],"award-info":[{"award-number":["821283"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020624","name":"NIHR Nottingham Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS-BRC-1215-20003"],"award-info":[{"award-number":["IS-BRC-1215-20003"]}],"id":[{"id":"10.13039\/501100020624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.toxlet.2026.113176","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:40:39Z","timestamp":1786117239000},"page":"113176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Utility of monocyte-derived cells to investigate immune-mediated drug-induced liver injury"],"prefix":"10.1016","volume":"424","author":[{"given":"Monique","family":"Ulepic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7913-759X","authenticated-orcid":false,"given":"Maria F.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-3952","authenticated-orcid":false,"given":"Stuart","family":"Astbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-7560","authenticated-orcid":false,"given":"Sibylle","family":"Pfammatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia L.","family":"Samodelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9950-7201","authenticated-orcid":false,"given":"Jane I.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9843-1559","authenticated-orcid":false,"given":"Nicholas R.F.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2026.113176_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67396-6","article-title":"Extracellular glucose is crucially involved in the fate decision of LPS-stimulated RAW264.7 murine macrophage cells","volume":"10","author":"Aki","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2026.113176_bib2","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/hep.20215","article-title":"HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease","volume":"39","author":"Andrade","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2026.113176_bib3","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.toxlet.2026.113176_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000374094","article-title":"Drug-induced liver injury and individual cell models","volume":"33","author":"Benesic","year":"2015","journal-title":"Dig. Dis."},{"key":"10.1016\/j.toxlet.2026.113176_bib5","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gutjnl-2015-309528","article-title":"Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury","volume":"65","author":"Benesic","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.toxlet.2026.113176_bib6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/labinvest.2012.64","article-title":"Human monocyte-derived cells with individual hepatocyte characteristics: a novel tool for personalized in vitro studies","volume":"92","author":"Benesic","year":"2012","journal-title":"Lab. Invest."},{"key":"10.1016\/j.toxlet.2026.113176_bib7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","article-title":"Criteria of drug-induced liver disorders. Report of an international consensus meeting","volume":"11","author":"Benichou","year":"1990","journal-title":"J. Hepatol."},{"key":"10.1016\/j.toxlet.2026.113176_bib8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-2776(02)80013-X","article-title":"Proteolysis and antigen presentation by MHC class II molecules","volume":"80","author":"Bryant","year":"2002","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.toxlet.2026.113176_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156873","article-title":"Immune checkpoint inhibitors mediate myocarditis by promoting macrophage polarization via cGAS\/STING pathway","volume":"187","author":"Cao","year":"2025","journal-title":"Cytokine"},{"key":"10.1016\/j.toxlet.2026.113176_bib11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib12","article-title":"Drug-induced liver injury associated with emerging cancer therapies","volume":"45","author":"Chodup","year":"2025","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.toxlet.2026.113176_bib13","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/ajhp\/zxz189","article-title":"Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma","volume":"76","author":"Choi","year":"2019","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.toxlet.2026.113176_bib14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1159\/000534023","article-title":"Metastatic melanoma treatment with pembrolizumab after hypersensitivity reaction to Nivolumab: a case report","volume":"16","author":"Cruse","year":"2023","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.toxlet.2026.113176_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.toxlet.2026.113176_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxlet.2026.113176_bib18","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","article-title":"Amoxicillin-clavulanate-induced liver injury","volume":"61","author":"deLemos","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.toxlet.2026.113176_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.toxlet.2026.113176_bib20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2174\/1389200211314090002","article-title":"Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering","volume":"14","author":"Donato","year":"2013","journal-title":"Curr. Drug. Metab."},{"key":"10.1016\/j.toxlet.2026.113176_bib21","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/jcp.24301","article-title":"Human monocyte-derived macrophages spontaneously differentiated in vitro show distinct phenotypes","volume":"228","author":"Eligini","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.toxlet.2026.113176_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2025.100238","article-title":"Hepatocytes derived from human induced pluripotent stem cells: towards establishing an in vitro model for assessing population variability in hepatotoxicity testing","volume":"8","author":"Gao","year":"2025","journal-title":"Curr. Res. Toxicol."},{"key":"10.1016\/j.toxlet.2026.113176_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.imlet.2022.08.002","article-title":"Conjugation of human serum albumin and flucloxacillin provokes specific immune response in HLA-B*57:01 transgenic mice","volume":"249","author":"Gao","year":"2022","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.toxlet.2026.113176_bib25","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acs.chemrestox.4c00067","article-title":"Immunological drug-drug interactions affect the efficacy and safety of immune checkpoint inhibitor therapies","volume":"37","author":"Grice","year":"2024","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.toxlet.2026.113176_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41512-023-00155-z","article-title":"Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control study","volume":"7","author":"Grove","year":"2023","journal-title":"Diagn. Progn. Res."},{"key":"10.1016\/j.toxlet.2026.113176_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.630530","article-title":"In-vitro approaches to predict and study T-cell mediated hypersensitivity to drugs","volume":"12","author":"Hammond","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxlet.2026.113176_bib28","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin-clavulanate--induced hepatitis","volume":"117","author":"Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib29","article-title":"vitro drug metabolism using liver microsomes","volume":"7","author":"Hill","year":"2004","journal-title":"Curr. Protoc. Pharmacol. Chapter"},{"issue":"1","key":"10.1016\/j.toxlet.2026.113176_bib30","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/bioinformatics\/18.suppl_1.S96","article-title":"Variance stabilization applied to microarray data calibration and to the quantification of differential expression","volume":"18","author":"Huber","year":"2002","journal-title":"Bioinformatics"},{"key":"10.1016\/j.toxlet.2026.113176_bib31","article-title":"Drugs and hepatic transporters: a review. Pharmacological research: the official journal of the Italian Pharmacological","volume":"154","author":"Jetter","year":"2020","journal-title":"Society"},{"key":"10.1016\/j.toxlet.2026.113176_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/09680519000060010501","article-title":"Lipopolysaccharide (LPS)-induced cell death of C3H mouse peritoneal macrophages in the presence of cycloheximide: different susceptibilities of C3H\/HeN and C3H\/HeJ mice macrophages","volume":"6","author":"Karahashi","year":"2000","journal-title":"J. Endotoxin Res."},{"key":"10.1016\/j.toxlet.2026.113176_bib33","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.tiv.2007.11.014","article-title":"Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran","volume":"22","author":"Kenne","year":"2008","journal-title":"Toxicol. Vitro Int. J. Publ. Assoc. BIBRA"},{"key":"10.1016\/j.toxlet.2026.113176_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41591-020-1023-0","article-title":"Polygenic architecture informs potential vulnerability to drug-induced liver injury","volume":"26","author":"Koido","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.toxlet.2026.113176_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1365-2567.1999.00904.x","article-title":"Granulocyte-macrophage colony-stimulating factor modulates lipopolysaccharide (LPS)-binding and LPS-response of human macrophages: inverse regulation of tumour necrosis factor-alpha and interleukin-10","volume":"98","author":"Kreutz","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.toxlet.2026.113176_bib36","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.toxlet.2026.113176_bib37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/aps.2008.19","article-title":"Heme oxygenase-1 mediates the anti-inflammatory effect of isoflurane preconditioning in LPS-stimulated macrophages","volume":"30","author":"Li","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.toxlet.2026.113176_bib38","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.21324","article-title":"Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain","volume":"44","author":"Lucena","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2026.113176_bib39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib40","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1002\/hep.21062","article-title":"Apoptosis and necrosis in the liver: a tale of two deaths?","volume":"43","author":"Malhi","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2026.113176_bib41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2002.31871","article-title":"Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats","volume":"35","author":"Masubuchi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2026.113176_bib42","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/acs.chemrestox.6b00253","article-title":"Amoxicillin and clavulanate form chemically and immunologically distinct multiple haptenic structures in patients","volume":"29","author":"Meng","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.toxlet.2026.113176_bib43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2026.113176_bib44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt.1375","article-title":"Drug-induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.toxlet.2026.113176_bib46","doi-asserted-by":"crossref","DOI":"10.1515\/jib-2022-0031","article-title":"Bridging data management platforms and visualization tools to enable ad-hoc and smart analytics in life sciences","volume":"19","author":"Panse","year":"2022","journal-title":"J. Integr. Bioinform"},{"key":"10.1016\/j.toxlet.2026.113176_bib47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2026.113176_bib48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.toxlet.2026.113176_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.toxlet.2026.113176_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.toxlet.2026.113176_bib51","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.toxlet.2026.113176_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-5793(95)01431-4","article-title":"Control of apoptosis by the cellular ATP level","volume":"378","author":"Richter","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.toxlet.2026.113176_bib53","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.toxlet.2026.113176_bib54","article-title":"Hepatotoxicity evaluation method through multiple-factor analysis using human pluripotent stem cell derived hepatic organoids","volume":"15","author":"Shin","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2026.113176_bib55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","article-title":"High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids","volume":"160","author":"Shinozawa","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2026.113176_bib56","doi-asserted-by":"crossref","first-page":"730","DOI":"10.21037\/atm-2020-ubih-05","article-title":"Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues","volume":"9","author":"Teschke","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.toxlet.2026.113176_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/0471140856.tx2305s54","article-title":"Membrane vesicle ABC transporter assays for drug safety assessment","author":"van Staden","year":"2012","journal-title":"Curr. Protoc. Toxicol. Chapter 23 Unit. 23 25"},{"key":"10.1016\/j.toxlet.2026.113176_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2018.08.001","article-title":"Primary hepatocytes and their cultures for the testing of drug-induced liver injury","volume":"85","author":"Vilas-Boas","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.toxlet.2026.113176_bib59","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/toxsci\/kfaa124","article-title":"Identification of flucloxacillin-haptenated HLA-B*57:01 ligands: evidence of antigen processing and presentation","volume":"177","author":"Waddington","year":"2020","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"10.1016\/j.toxlet.2026.113176_bib60","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1021\/acs.jproteome.2c00441","article-title":"prolfqua: a comprehensive R-package for proteomics differential expression analysis","volume":"22","author":"Wolski","year":"2023","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.toxlet.2026.113176_bib61","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.4049\/jimmunol.1202949","article-title":"HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin","volume":"190","author":"Wuillemin","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.toxlet.2026.113176_bib62","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.toxlet.2026.113176_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027940","article-title":"Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis","volume":"9","author":"Yang","year":"2019","journal-title":"BMJ Open."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427426013597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427426013597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:15:57Z","timestamp":1788617757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427426013597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":63,"alternative-id":["S0378427426013597"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2026.113176","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of monocyte-derived cells to investigate immune-mediated drug-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2026.113176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113176"}}